# Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

> **NCT06871527** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 44 (estimated)

## Conditions studied

- Gastric (Stomach) Cancer
- Gastric Adenocarcinoma
- Fruquintinib
- PD-1 Inhibitor
- Tislelizumab
- GEJ Adenocarcinoma

## Interventions

- **DRUG:** fruquintinib + tislelizumab + FOLFOX

## Key facts

- **NCT ID:** NCT06871527
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06871527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06871527, "Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06871527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*